
|Articles|May 22, 2007
ATS: COPD Drugs Slow Disease Progression, Study Confirms
SAN FRANCISCO -- Inhaled corticosteroid and long-acting beta2 agonist therapy significantly slows the progressive lung function decline of chronic obstructive pulmonary disease (COPD).
Advertisement
SAN FRANCISCO, May 22 -- Inhaled corticosteroid and long-acting beta2 agonist therapy significantly slows the progressive lung function decline of chronic obstructive pulmonary disease (COPD).
Fluticasone proprionate plus salmeterol (Advair) reduced the decline in forced expiratory volume (FEV1) by 16 mL per year compared with placebo (P
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Healthiest States in America: A 2025 Ranking
2
Nationwide Survey Finds Widespread Concern About Topical Steroid Use, Emphasizes Need for Long-Term Management Strategies in Chronic Inflammatory Skin Disease
3
Sebela Submits NDA for Tegoprazan for GERD, Seeking Approval for NERD and Erosive Esophagitis
4
Avoiding Common Ordering Errors in UACR Testing, With Holly Kramer, MD
5























































































































































































































































































































